Detailed analysis of cell cycle kinetics upon proteasome inhibition
β Scribed by Barbie M. Machiels; Mieke E. R. Henfling; Will L. H. Gerards; Jos L. V. Broers; Hans Bloemendal; Frans C. S. Ramaekers; Bert Schutte
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 275 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
β¦ Synopsis
We have studied specific effects of proteasome inhibition on cell cycle progression. To this end, the protease inhibitors MG115, calpain inhibitor I, and calpain inhibitor II, which display differential inhibitory effects on proteasomes, were used. Cell kinetic studies using bromodeoxyuridine pulse labeling revealed a complete block of G1/S and metaphase transitions and a delayed progression through S phase in cell cultures treated with 54 Β΅M of MG115. Calpain inhibitor I in similar concentrations displayed a fivefold lower effect on cell cycle kinetics. Calpain inhibitor II and MG2M, which is a structural analogue of MG115, had no effect on the cell cycle. The inhibitory effect of MG115 treatment was reversible, because the cell cycle was immediately resumed when the MG115-containing culture medium was replaced by fresh culture medium. Because ubiquitinated proteins accumulated after MG115 treatment, it was confirmed that ubiquitin-dependent protein degradation, and thus proteasomal activity were blocked. By comparison of biochemical and in vitro proteasome inhibition experiments, it was hypothesized that chymotrypsin-like activity of proteasomes may play an important role in cell cycle kinetics.
π SIMILAR VOLUMES
A computer simulation model was developed and used to analyze the inhibitory effect of aphidicolin on the proliferation of Hela cells. Simulation results were compared with actual experimental results [Pedrali-Noy et al. (1980) Nuc. Acid Res. 8, 377] and were found to be in good agreement. Also, the
alpha-Difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, was used alone and in combination with multiple doses of methylglyoxal-bis(guanylhydrazone) (MGBG) to treat mice with systemic L1210 leukemia. Used as a single agent (administered p.o. as a 3
## Abstract Active Ras contributes to the malignant phenotype of glioblastoma multiforme. Recent studies showed that the Ras inhibitor farnesyl thiosalicylic acid downregulates the transcription factor hypoxiaβinducible factorβ1Ξ±, causing shutdown of glycolysis in U87 glioblastoma cells. Farnesyl t